SCHEMBL13102453

SCHEMBL13102453

O=C(Cc1ccccc1)Nn1c(C2CC2)nc2c(C3CC3)cccc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
ATM Q13315 1/20 0.47
NPSR1 Q6W5P4 1/20 0.45
HTT P42858 3/20 0.45
TSHR P16473 4/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
GLS O94925 2/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102473 0.91 SMN1; SMN2 (0.43) ALDH1A1ATMNPSR1HTTTSHR
SCHEMBL13102191 0.88 ALDH1A1 (0.46) ALDH1A1ATMNPSR1HTTTSHR
SCHEMBL13102514 0.88 NPSR1 (0.46) ALDH1A1ATMNPSR1HTTTSHR
SCHEMBL13102387 0.86 ALDH1A1 (0.44) ALDH1A1ATMNPSR1HTTTSHR
SCHEMBL13102017 0.84 ALDH1A1 (0.43) ALDH1A1NPSR1HTTRAB9ALMNA
SCHEMBL13102085 0.83 ALDH1A1 (0.45) ALDH1A1ATMNPSR1HTTTSHR
SCHEMBL13102456 0.82 ALDH1A1 (0.45) ALDH1A1ATMNPSR1HTTTSHR
SCHEMBL13102187 0.81 SMN1; SMN2 (0.43) ALDH1A1ATMNPSR1HTTTSHR
SCHEMBL13102517 0.80 ALDH1A1 (0.40) ALDH1A1ATMNPSR1HTTTSHR
SCHEMBL13102202 0.80 PDE1C (0.42) ALDH1A1ATMNPSR1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329713-B2 Fused ring heterocycles as potassium channel modulators ICAGEN INC. (US) 2012-12-11 US disclosed
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNK17, KCNJ2, KCNJ1 ALDH1A1 2354/4885ATM 1284/4885NPSR1 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.